Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Influence of Food Regimen on Oshadi D Absorption

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Oshadi Drug Administration
ClinicalTrials.gov Identifier:
NCT01327352
First received: March 29, 2011
Last updated: June 20, 2012
Last verified: June 2012
  Purpose

The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects. The study will include one administration of placebo and four single administrations of Oshadi D in two different dose levels, administered in two feeding regimen for the evaluation of the influence of food on Oshadi D absorption.


Condition Intervention
Lupus Erythematosus, Systemic
Drug: Oshadi D

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Single Center, Non-randomized, Placebo Controlled Study for the Evaluation of the Influence of Food Regimen on Oshadi D Absorption

Resource links provided by NLM:


Further study details as provided by Oshadi Drug Administration:

Primary Outcome Measures:
  • DNase activity level (Kunitz/mL) for 2 dose levels, and different food regimen [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Maximum plasma DNase concentration (ng/mL) in different food regimen and dose levels [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: April 2011
Study Completion Date: October 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oshadi D

2 dose levels of Oshadi D in 2 food regimen will be administered as following:

  • Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.
  • On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration
  • On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.
  • On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.
  • On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast.
Drug: Oshadi D
oral administration

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Male/female 21 years old and up.
  • Subject must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
  • Subject must be sterile or infertile or use an approved method of contraception from the time that the first dose of study medication is taken until three months following study completion or discontinuation.

Exclusion Criteria:

  • Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
  • Subject with positive HIV serology or positive HBsAg at screening.
  • History or evidence of any active liver disease.
  • Female subject who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
  • Inability to give written informed consent
  • History of alcohol or drug abuse within 6 months of screening.
  • Subject who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
  • Mental disorders.
  • Subject with poor venous access
  • Significant swallowing disorders
  • Digestive disorders;
  • Small bowel surgery;
  • Mall absorption disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01327352

Locations
Israel
Assaf Harofe Medical Center,
Zrifin, Israel
Sponsors and Collaborators
Oshadi Drug Administration
Investigators
Principal Investigator: Keren Duanis, MD Assaf Harofe Medical Center, Israel
Study Director: Hanna Levy, Dr. Oshadi Drug Administration
  More Information

No publications provided

Responsible Party: Oshadi Drug Administration
ClinicalTrials.gov Identifier: NCT01327352     History of Changes
Other Study ID Numbers: OS-DN-P1b-01
Study First Received: March 29, 2011
Last Updated: June 20, 2012
Health Authority: Israel: Ethics Commission

Keywords provided by Oshadi Drug Administration:
lupus

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on November 20, 2014